Oslo Sports Trauma Research Center, Norwegian School of Sport Sciences, Oslo, Norway Correspondence to Benjamin Clarsen, Oslo Sports Trauma Research Center, Norwegian School of Sport Sciences, PO Box ...
The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results